All Posts

Merck’s Chronic Cough Med Gefapixant Receives A Red Flag From the FDA, Requests For More Data On 24th January 2022, Merck & Co. announced FDA rejection for its New Drug Application (NDA) of Gefapixant (experimental drug) for unexplained or chronic cough. FDA asked for additional information on the drug, rela...

Highlights: The key challenges in the clinical trials processes such as slow recruitment, data management, lack of diversity, compliance with several rules and regulations, and others faced by the organizations.The impact of technology in clinical trials from recruiting more quickly to remote monitoring and impr...

Beta Thalassemia (β-Thalassemia) is a blood disorder characterized by reduced synthesis of the hemoglobin subunit beta (hemoglobin beta chain) that results in microcytic hypochromic anemia, an abnormal peripheral blood smear with nucleated red blood cells, and reduced amounts of hemoglobin A (HbA) on hemoglobin ana...

Suneva Medical Inc. inked a merger agreement with Viveon Health On January 12, 2022, Suneva Medical Inc., a leading regenerative aesthetics company, and Viveon Health Acquisition Corp., a particular purpose acquisition company, entered into a definitive merger agreement to establish a new regenerative aesthetics...

It's no longer startling to learn that the best-performing surgeon at a hospital isn't human. With their unrivaled precision and ability to work without fatigue, medical robots are one of the most valuable applications of robotics in the healthcare industry. These robots are used in various medical scenarios, inclu...

Algernon receives positive FDA feedback on Phase IIb chronic cough trial The US Food and Drug Administration (FDA) has given positive feedback for Algernon Pharmaceuticals’ Phase IIb clinical trial of NP-120 (ifenprodil) for chronic cough treatment.  A receptor antagonist of N-methyl-D-aspartate (NMDA), ifenp...

As the name suggests, Neuroprosthetics is a combination of neural processing with prosthetics. The Neuroprosthetics devices interface with the human brain to control artificial limbs. These are different from the traditional prosthetics as it’s more closely aligned to how the human body functions and works via a br...

The innovation in the oncology drug pipeline has resulted in a record number of FDA and EU approvals in recent years, as investigators and sponsors seek new and targeted treatments for individuals diagnosed with different types of cancers each year. In 2022, regulators will continue to evaluate new oncology therapi...

Leman Micro Devices tested against the cuffed blood measurement devices reported positive results  On January 07, 2022, the e-Checkup system by Leman Micro Devices tested in the world’s first clinical trial against the cuffed blood measurement devices reported positive results.  The e-Checkup and its sma...

In the year 2000, the first-ever Antibody-drug Conjugate (ADC) - Mylotarg, was launched by Pfizer and was considered a miracle in cancer treatment. And it appeared like there was no looking back for these antibody-drug conjugates. But it took almost another 11 years for the next ADC to launch in the market - Adectr...